Fenwick Represents Sema4 in Combination Agreement With CM Life Sciences SPAC

Fenwick represented Sema4, a patient-centered genomic and clinical data intelligence company, in its definitive business combination agreement with CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital and Corvex Management.

The transaction values Sema4 at approximately $2 billion. It is expected to deliver up to $793 million of gross proceeds to shareholders and Sema4, including $443 million held in CM Life Sciences’ trust account from its initial public offering in September 2020 and $350 million from committed equity PIPE funding from a group of institutional and life sciences investors.

The transaction is expected to close in the second quarter of 2021, subject to the approval of the CM Life Sciences shareholders and other customary conditions. More information can be obtained from the company’s announcement.

The Fenwick transaction team for included corporate partners Ethan Skerry, Robert Freedman and David Michaels, associates Victoria Lupu, Steven Jean, Kristin Esannason, Kristen Nicol, Cedrick Dalluge, Sarah Hill and Jennifer Wu; executive compensation & employee benefits partner Matthew Cantor and associates Corinne Nhaissi and Cynthia Yuan; technology transactions partner Jake Handy and associates Jennifer Yoon, Jefferson Lin, Lauren Kim and law clerk Zach Harned; antitrust & trade regulation partner Mark Ostrau; privacy & cybersecurity counsel Helen Christakos; and tax partner David Forst and associate Timmoney Ng.